AGIOS PHARMACEUTICALS, INC. reported the quarter ended March 31, 2026 results: net income $99.1 million.
“For the quarter ended March 31, 2026, net loss was $99.1 million, compared to net loss of $89.3 million for the quarter ended March 31, 2025.”
AGIOS PHARMACEUTICALS, INC. — fact timeline
Source-grounded facts extracted from AGIOS PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
David P. Schenkein, M.D. resigned as Director at AGIOS PHARMACEUTICALS, INC..
“On February 10, 2025, David P. Schenkein, M.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective February 28, 2025.”
AGIOS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2024 results: revenue $8.2 million.
“RISE UP Study in Sickle Cell Disease, ACTIVATE-KIDS and ACTIVATE KIDS-T in Pediatric PK Deficiency, All Expected by End of 2025 – – PYRUKYND® (Mitapivat) Net Revenue of $8.2 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $714.3 Million as of March 31, 2024 – CAMBRIDGE, Mass., May 2, 2024 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.